Applegate W B, Carper E R, Kahn S E, Westbrook L, Linton M, Baker M G, Runyan J W
J Am Geriatr Soc. 1985 Feb;33(2):109-15. doi: 10.1111/j.1532-5415.1985.tb02275.x.
A retrospective chart analysis was conducted on all new elderly hypertensive patients referred to a community hypertension clinic who were being treated with either reserpine or alpha-methyldopa plus a diuretic. There were no significant differences between the two groups on entry in age, gender, co-morbid diagnoses, or systolic or diastolic blood pressure. There were no significant differences between the two groups in terms of side effects over three years, but the proportion of persons having compliance problems was significantly lower in the reserpine group. Mean diastolic pressures were significantly lower after one, two, and three years, and systolic pressures were lower after one and two years in the reserpine group. Reserpine is at least as effective as alpha-methyldopa in treating hypertension in the elderly and is associated with fewer problems in compliance.
对转诊至社区高血压诊所、正在接受利血平或甲基多巴加利尿剂治疗的所有老年高血压新患者进行了回顾性病历分析。两组患者在年龄、性别、合并症诊断、收缩压或舒张压方面在入组时无显著差异。两组在三年间的副作用方面无显著差异,但利血平组出现依从性问题的患者比例显著更低。利血平组在1年、2年和3年后平均舒张压显著更低,在1年和2年后收缩压更低。在治疗老年高血压方面,利血平至少与甲基多巴一样有效,且依从性问题更少。